Cargando…
Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus h...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771608/ https://www.ncbi.nlm.nih.gov/pubmed/35058587 http://dx.doi.org/10.1038/s41401-021-00851-w |
_version_ | 1784635645720788992 |
---|---|
author | Wu, Can-rong Yin, Wan-chao Jiang, Yi Xu, H. Eric |
author_facet | Wu, Can-rong Yin, Wan-chao Jiang, Yi Xu, H. Eric |
author_sort | Wu, Can-rong |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus has been greatly enhanced over the past 2 years. Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19. In this review, we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed. We present the examples of structure-based design of Pfizer’s novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck’s nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies. |
format | Online Article Text |
id | pubmed-8771608 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-87716082022-01-20 Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 Wu, Can-rong Yin, Wan-chao Jiang, Yi Xu, H. Eric Acta Pharmacol Sin Review Article Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus has been greatly enhanced over the past 2 years. Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19. In this review, we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed. We present the examples of structure-based design of Pfizer’s novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck’s nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies. Springer Nature Singapore 2022-01-20 2022-12 /pmc/articles/PMC8771608/ /pubmed/35058587 http://dx.doi.org/10.1038/s41401-021-00851-w Text en © The Author(s), under exclusive licence to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society 2022 |
spellingShingle | Review Article Wu, Can-rong Yin, Wan-chao Jiang, Yi Xu, H. Eric Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title_full | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title_fullStr | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title_full_unstemmed | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title_short | Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19 |
title_sort | structure genomics of sars-cov-2 and its omicron variant: drug design templates for covid-19 |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771608/ https://www.ncbi.nlm.nih.gov/pubmed/35058587 http://dx.doi.org/10.1038/s41401-021-00851-w |
work_keys_str_mv | AT wucanrong structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19 AT yinwanchao structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19 AT jiangyi structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19 AT xuheric structuregenomicsofsarscov2anditsomicronvariantdrugdesigntemplatesforcovid19 |